Antitumor Drug Market Synopsis:
In this report, LP Information studies the present scenario with the base year being 2017 and the growth prospects of global Antitumor Drug market for 20182023.
Antitumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as largescale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of antitumor drugs have been into a new era.
In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other wellknown domestic enterprises in the antitumor drugs have invested a lot of money, there are many innovative anticancer drugs into the clinical research stage. In the meantime, there has been “explosive” growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.
Chinas biopharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of biopharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th FiveYear Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the biopharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall welltodo society. Mainly manifested in: smallscale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the longterm development of biomedical industry , Deepseated problems still exist.
Over the next five years, LPILP Information projects that Antitumor Drug will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares and growth opportunities of Antitumor Drug market by product type, application, key companies and key regions.
To calculate the market size, LP Information considers value generated from the sales of the following segments:
Segmentation by product type:
Cytotoxic Drugs
Noncytotoxic Drugs
Segmentation by application:
Alkylating Agents
Antimetabolism Drugs
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
We can also provide the customized separate regional or countrylevel reports, for the following regions:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Roche
Novartis
Celgene
BristolMyers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Antitumor Drug market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Antitumor Drug market by identifying its various subsegments.
Focuses on the key global Antitumor Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Antitumor Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market growth potential, opportunities, drivers, industryspecific challenges and risks.
To project the size of Antitumor Drug submarkets, with respect to key regions along with their respective key countries.
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
